Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial

被引：0
|
作者：
Ignacio Martin-Loeches
Andrew F. Shorr
Richard G. Wunderink
Marin H. Kollef
Jean-François Timsit
Brian Yu
Jennifer A. Huntington
Erin Jensen
Christopher J. Bruno
机构：
[1] St James’ Hospital,
[2] Universitat de Barcelona,undefined
[3] IDIBAPS,undefined
[4] CIBERes,undefined
[5] Georgetown University,undefined
[6] Northwestern University Feinberg School of Medicine,undefined
[7] Washington University School of Medicine,undefined
[8] APHP Medical and Infectious Diseases ICU,undefined
[9] Bichat Hospital Université Paris Cité,undefined
[10] Merck & Co.,undefined
[11] Inc.,undefined
来源：
Annals of Intensive Care | / 13卷
关键词：
ASPECT-NP; Gram-negative; Nosocomial; Pneumonia; Shock; SOFA;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 22 条
  • [11] Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial
    Shorr, Andrew F.
    Bruno, Christopher J.
    Zhang, Zufei
    Jensen, Erin
    Gao, Wei
    Feng, Hwa-Ping
    Huntington, Jennifer A.
    Yu, Brian
    Rhee, Elizabeth G.
    De Anda, Carisa
    Basu, Sumit
    Kollef, Marin H.
    CRITICAL CARE, 2021, 25 (01)
  • [12] Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia
    Martin-Loeches, Ignacio
    Timsit, Jean-Francois
    Kollef, Marin H.
    Wunderink, Richard G.
    Shime, Nobuaki
    Novacek, Martin
    Kivistik, Ulo
    Rea-Neto, Alvaro
    Bruno, Christopher J.
    Huntington, Jennifer A.
    Lin, Gina
    Jensen, Erin H.
    Motyl, Mary
    Yu, Brian
    Gates, Davis
    Butterton, Joan R.
    Rhee, Elizabeth G.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2022, 77 (04) : 1166 - 1177
  • [13] Molecular Characterization of Baseline Enterobacterales and Pseudomonas aeruginosa Isolates from a Phase 3 Nosocomial Pneumonia (ASPECT-NP) Clinical Trial
    Castanheira, Mariana
    Johnson, Matthew G.
    Yu, Brian
    Huntington, Jennifer A.
    Carmelitano, Patricia
    Bruno, Christopher
    Rhee, Elizabeth G.
    Motyl, Mary
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (03)
  • [14] Ceftolozane/tazobactam for hospital-acquired/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial
    Paterson, David L.
    Bassetti, Matteo
    Motyl, Mary
    Johnson, Matthew G.
    Castanheira, Mariana
    Jensen, Erin H.
    Huntington, Jennifer A.
    Yu, Brian
    Wolf, Dominik J.
    Bruno, Christopher J.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2022, 77 (09) : 2522 - 2531
  • [15] Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP)
    Johnson, Matthew G.
    Bruno, Christopher
    Castanheira, Mariana
    Yu, Brian
    Huntington, Jennifer A.
    Carmelitano, Patricia
    Rhee, Elizabeth G.
    De Anda, Carisa
    Motyl, Mary
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2021, 57 (03)
  • [16] Safety and Efficacy of Ceftolozane/Tazobactam Plus Metronidazole Versus Meropenem From a Phase 2, Randomized Clinical Trial in Pediatric Participants With Complicated Intra-abdominal Infection
    Jackson, Carl-Christian A.
    Newland, Jason
    Dementieva, Nataliia
    Lonchar, Julia
    Su, Feng-Hsiu
    Huntington, Jennifer A.
    Bensaci, Mekki
    Popejoy, Myra W.
    Johnson, Matthew G.
    De Anda, Carisa
    Rhee, Elizabeth G.
    Bruno, Christopher J.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2023, 42 (07) : 557 - 563
  • [17] A phase III, multicenter, double-blind, randomized clinical trial to evaluate the efficacy and safety of ceftolozane/tazobactam plus metronidazole versus meropenem in Chinese participants with complicated intra-abdominal infections
    Sun, Yihong
    Fan, Jia
    Chen, Gang
    Chen, Xiaofei
    Du, Xiaoling
    Wang, Ye
    Wang, Hui
    Sun, Fang
    Johnson, Matthew G.
    Bensaci, Mekki
    Huntington, Jennifer A.
    Bruno, Christopher J.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2022, 123 : 157 - 165
  • [18] Efficacy and Safety of Ceftaroline Fosamil in Hospitalized Patients with Community-Acquired Pneumonia in China: Subset Analysis of an International Phase 3 Randomized Controlled Trial
    Zhuo, Chao
    Huang, Yijiang
    Liu, Wenyuan
    Xu, Jin-Fu
    Zhu, Wei Yun
    Stone, Gregory G.
    Yan, Jean Li
    Mohamed, Naglaa
    INFECTION AND DRUG RESISTANCE, 2022, 15 : 605 - 617
  • [19] Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial
    Wunderink, Richard G.
    Matsunaga, Yuko
    Ariyasu, Mari
    Clevenbergh, Philippe
    Echols, Roger
    Kaye, Keith S.
    Kollef, Marin
    Menon, Anju
    Pogue, Jason M.
    Shorr, Andrew F.
    Timsit, Jean-Francois
    Zeitlinger, Markus
    Nagata, Tsutae D.
    LANCET INFECTIOUS DISEASES, 2021, 21 (02): : 213 - 225
  • [20] Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial
    Tanaka, Yoshiya
    Bass, Damon
    Chu, Myron
    Egginton, Sally
    Ji, Beulah
    Roth, David
    MODERN RHEUMATOLOGY, 2020, 30 (02) : 313 - 320
123